Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Company
Gyre Therapeutics, Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $5.81
-11% in 3d after detection
Post-detection moves
1h
—
1d
-1.8%
3d
-11%
7d
-8.1%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS